Kazia Therapeutics Limited KZIA
Set alert
8.02 USD -0.48 -5.65%
At close · Nov 2
8.65 +0.63 +7.86%
After hours · Nov 2, 4:00 PM ET
7.80 Day range 8.75
4.86 52-week range 17.40
- YTD
- +16.40%
- 1 year
- +2.69%
- Open
- 8.63
- Prev close
- 8.50
- Mkt cap
- 91.64M
- Vol
- 156.04K
- Avg vol
- 270.87K
- EPS
- -6.46
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 7.80
- High
- 8.75
- Forward P/E
- 0.00
- Beta
- 2.08
- Short ratio
- 0.11
- Inst. own
- 7.06%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 4.90
- 200-d avg
- 3.80
- 1y target
- 0.00
2Y chart
Events in this range
- Apr 17, 2025Split: 1 for 5
Signals (96)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 13, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 7, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| MACD: Sell Signal | Sep 1, 2026 | 2 months ago |
| RSI: Overbought | Aug 27, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| SMA: Bearish | Aug 21, 2026 | 2 months ago |
| SMA: Bullish | Aug 13, 2026 | 2 months ago |
| SMA: Bearish | Aug 12, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| SMA: Bearish | Jul 23, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 23, 2026 | 3 months ago |
Newest 20 of 96.
Key statistics
- Market cap
- 12.93M
- Enterprise value
- 1.20B
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 23096.84
- Price / book
- 1.49
- EPS (TTM)
- -6.44
- Beta
- 2.08
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 560
- Revenue growth
- 0.00%
- Free cash flow
- -6.57M
- Total cash
- 3.56M
- Total debt
- 359.30K
- Return on equity
- -186.37%
- Shares outstanding
- 4.35M
- Short % of float
- 1.68%
- 50-day average
- 4.90
- 200-day average
- 3.80
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
KZIA Revenue — annual 1.83M
KZIA Net income — annual -20.70M
KZIA EPS — annual -3.78
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 11, 2023 | HC Wainwright & Co. | up | Neutral | Buy |
| Aug 2, 2022 | Maxim Group | down | Buy | Hold |
| Aug 2, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Oct 14, 2021 | Maxim Group | init | — | Buy |
| Jan 5, 2021 | HC Wainwright & Co. | init | — | Buy |
About Kazia Therapeutics Limited
Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- Website
- kaziatherapeutics.com
News
- Kazia Therapeutics Says Two Abstracts Highlighting Paxalisib Tumor And Immune Reprogramming Research Accepted For Poster Presentation At 2026 San Antonio Breast Cancer Symposium
- Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium
- This Kazia Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
- Needham Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $27
- Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference
- This Equinix Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
- Guggenheim Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $35
- Leerink Partners Initiates Coverage On Kazia Therapeutics with Outperform Rating, Announces Price Target of $30
- Kazia Therapeutics Announces Sovargen Doses First Participant In Phase 1b/2a Clinical Study Of Paxalisib To Treat Epilepsies
- Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
Your note
Sign in to keep a note on KZIA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| MAI Capital Management | 3.13% | 136,389 | 405.07K | Sep 29, 2024 |
| UBS Group AG | 0.57% | 24,945 | 74.09K | Sep 29, 2024 |
| Morgan Stanley | 0.51% | 22,026 | 65.42K | Sep 29, 2024 |
| Captrust Financial Advisors | 0.35% | 15,265 | 45.34K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.14% | 6,048 | 17.96K | Sep 29, 2024 |
| Jane Street Group, LLC | 0.11% | 4,611 | 13.69K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.03% | 1,478 | 4.39K | Oct 30, 2024 |